Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
We discuss results from two new studies, which looked at real-world outcomes of subsequent therapies in patients whose disease progressed after either 1) double-exposure to a covalent BTK inhibitor and venetoclax or 2) exposure to a non-covalent BTK inhibitor.
Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double Refractory)
We discussed an analysis of acquired mutations in patients from the MURANO trial whose disease had progressed.
We discussed an ongoing clinical trial currently recruiting patients to see if early intervention with venetoclax plus obinutuzumab can produce better outcomes for high-risk patients compared with traditional delayed therapy.
At the American Society of Hematology (ASH) 2021, Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center, interviewed Dr. Nitin Jain, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. They discussed early results from an ongoing study of a triple combination therapy with venetoclax, obinutuzumab, and atezolizumab, a PD-L1 checkpoint inhibitor.
Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.
CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at the 2021 ASH meeting.
At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a tolerable level of adverse events (AE).
Here we review ReVenG, a phase 2 study of venetoclax plus obinutuzumab retreatment (“second time”) in patients with relapsed chronic lymphocytic leukemia (CLL) (ClinicalTrials.gov Identifier: NCT04895436) that fits that category. It was presented at ASH 2021 by Dr. Matthew Davids.
One click to our most popular content.
